Researcher
Rob BIELEN
- Keywords:Medicine, Biomedical sciences (incl. biochemistry)
- Disciplines:Hepatology, Epidemiology
Affiliations
- Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Jan 2021 → 31 Dec 2021 - Limburg Clinical Research Center (Research Center)
Member
From1 Jan 2021 → 31 Dec 2021 - Immunology & Infection (Research group)
Member
From1 Jan 2021 → 31 Dec 2021 - Immunology & Infection (Department)
Member
From1 Jan 2021 → 31 Dec 2021 - Immunology & Infection (Department)
Member
From1 Jan 2020 → 31 Jul 2020 - Immunology & Infection (Research group)
Member
From1 Jan 2020 → 31 Jul 2020 - Limburg Clinical Research Center (Research Center)
Member
From1 Jan 2020 → 31 Jul 2020 - Faculty of Medicine and Life Sciences (Faculty)
Member
From1 Aug 2015 → 31 Jul 2020 - Physiology - Biochemistry - Immunology (Department)
Member
From1 Aug 2015 → 31 Dec 2019 - Immunology - Biochemistry (Research group)
Member
From1 Aug 2015 → 31 Dec 2019
Publications
31 - 39 of 39
- Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation(2017)
Authors: Rob BIELEN, Geert ROBAEYS, S. Schelfhout, D. Monbaliu, S. Van der Merwe, J. Pirenne, F. Nevens
Pages: S441 - S441 - Belgian experience with direct acting antivirals in people who inject drugs(2017)
Authors: Rob BIELEN, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, et al.
Pages: 214 - 220 - The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience(2017)
Authors: Rob BIELEN, C. Moreno, H. Van Vlierberghe, S. Bourgeois, J. -P. Mulkay, S. Francque, W. Verlinden, C. Brixko, J. Decaestecker, C. De Galocsy, et al.
Pages: S623 - S624 - The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience(2017)
Authors: Rob BIELEN, C. Moreno, H. Van Vlierberghe, S. Bourgeois, J. -P. Mulkay, T. Vanwolleghem, W. Verlinden, C. Brixco, J. Decaestecker, C. de Galocsy, et al.
Pages: 976 - 981 - Case Management to Improve Uptake for Screening and Therapy of Hepatitis C viral infection in People Who Inject Drugs.(2016)
Authors: Rob BIELEN, Rita Verrando, Joris PENDERS, Els Oris, Frederik Nevens, Geert ROBAEYS
Pages: 411A - 412A - Global genotype distribution of hepatitis C viral infection among people who inject drugs(2016)
Authors: Rob BIELEN, Geert ROBAEYS, Ghezel Azar Darush, Homie Razavi, Frederik Nevens
Pages: S522 - S523 - Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs.(2016)
Authors: Rob BIELEN, Hans Van Vlierberghe, Stefan Bourgeois, Christophe Moreno, Thomas Vanwollegem, Wim Verlinden, Jean-Pierre Mulkay, Jochen Decaestecker, Mike Cool, Chantal de Galocsy, et al.
Pages: 457A - 457A - Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs(2016)
Authors: Rob BIELEN, Hans Van Vlierberghe, Stefan Bourgeois, Christophe Moreno, Thomas Vanwollegem, Wim Verlinden, Jean-Pierre Mulkay, Jochen Decaestecker, Mike Cool, Chantal de Galocsy, et al.
Pages: 457A - 457A - Global genotype distribution of hepatitis C viral infection among people who inject drugs(2016)
Authors: Rob BIELEN, Geert ROBAEYS, Ghezel Azar Darush, Homie Razavi, Frederik Nevens
Pages: 1094 - 1103
Linked dataset
1 - 1 of 1